UCB S.A.

A global biopharma company, inspired by the needs of people living with severe diseases. At UCB, we are consistently delivering on our commitment to improve the lives of people living with severe neurological and immunological conditions. And thanks to our focused, innovative and trusted solutions, our business is strong, with total revenue reaching €5.5 billion in 2022. This success is powered by the approximately 8,700 people – from our headquarters in Belgium and across nearly 40 countries worldwide. Our people have lived our purpose each day since 1928, making critical investments in biopharmaceutical research and leading innovations that strive to achieve a meaningful impact on the lives of those we serve.